Home
Fresenius Kabi

Fresenius Kabi Market Share Analysis for July 2026

Discover our dedication to quality and our Code of Conduct.

Health > Biotechnology and Pharmaceuticals

Domainfresenius-kabi.com

Year Founded1999

Employees> 10001

Annual Revenue> $1B

Fresenius Kabi

Fresenius Kabi (including company regionals)

fresenius-kabi.com

See more website traffic and engagement information

Fresenius Kabi Revenue up to July 2026 is > 1B

revenue generated by Fresenius Kabi top domains

Fresenius Kabi top domains revenue over 3 years

Revenue for Fresenius Kabi top domains

fresenius-kabi.com> 1B

See more with Sales Intelligence

Total visits to Fresenius Kabi's top domains

Understand Fresenius Kabi market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

fresenius-kabi.com222K

See more with Sales Intelligence

Avg. visit duration in Fresenius Kabi's top domains

Analyze Fresenius Kabi engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

fresenius-kabi.com00:01:03

See more with Sales Intelligence

Avg. pageviews on Fresenius Kabi's top domains

See how Fresenius Kabi keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

fresenius-kabi.com2.28

See more with Sales Intelligence

Fresenius Kabi top competitors by domain

Top similar sites in July 2026, ranked by their affinity

fresenius.comCompany NameFreseniusEmployees> 10001HQGermany, Bad HomburgAnnual revenue> $1BTotal visits90KHealth > Health - Other

Top technologies used by Fresenius Kabi

These are the website technologies, by industry, used by Fresenius Kabi top domains

Conversion & Analytics (6)

Matomo (Previously Piwik)

Marketing (5)

Google Marketing Platform

Payment & Currencies (4)

Visa

Advertising (3)

DoubleClick

More Technologies

12

See all

News & Signals from Fresenius Kabi

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsFresenius Kabi launches rituximab biosimilar.Building on the momentum of the vedolizumab regulatory submissions, Fresenius Kabi also announced FDA approval of its rituximab biosimilar, developed by Dr. Reddy's Laboratories as a biosimilar to Rituxan(R)(rituximab).

NewsFresenius Kabi identified as competitor of Takeda Pharmaceutical Co. on Jul 31st '26.On July 31, 2026, Fresenius Kabi and Polpharma announced the FDA acceptance of their aBLA for PB016 (vedolizumab), a proposed intravenous biosimilar of Takeda's Entyvio(R)(vedolizumab).

NewsFresenius Kabi was planning to develop Vedolizumab Biosimilar candidate on Jul 31st '26.Fresenius Announces FDA and EMA acceptance for review of Vedolizumab Biosimilar candidate.